Login / Signup

Post-Chimeric Antigen Receptor T-Cell Therapy Hepatitis B Virus Reactivation After 23 Months of Entecavir Prophylaxis.

Caleb J C McKinneyWilliam BigelowPreethi G VenkatNeeral L Shah
Published in: ACG case reports journal (2024)
Hepatitis B virus (HBV) reactivation can occur in immunosuppressed patients. Specifically, HBV reactivation after chimeric antigen receptor T-cell (CAR T-cell) therapy is a known complication with few case reports and specific treatment guidelines. Our patient experienced HBV reactivation 27 months after CAR T-cell therapy even with 23 months of entecavir prophylaxis. This unique case highlights the need for further investigation into the risk of HBV reactivation after CAR T-cell therapy and the proper HBV prophylaxis during and after CAR T-cell therapy.
Keyphrases
  • cell therapy
  • hepatitis b virus
  • stem cells
  • liver failure
  • mesenchymal stem cells
  • end stage renal disease
  • case report
  • chronic kidney disease
  • newly diagnosed
  • peritoneal dialysis
  • bone marrow
  • combination therapy